Barinthus Biotherapeutics plc
BRNS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $14,969 | $802 | $44,703 | $268 |
| % Growth | 1,766.5% | -98.2% | 16,580.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $14,969 | $802 | $44,703 | $268 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $38,253 | $41,413 | $41,110 | $16,370 |
| G&A Expenses | $29,670 | $39,842 | $6,394 | $25,118 |
| SG&A Expenses | $29,670 | $39,842 | $6,394 | $25,118 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $15,016 | $3,461 | $1,240 | $4,001 |
| Operating Expenses | $82,939 | $84,716 | $48,744 | $45,489 |
| Operating Income | -$67,970 | -$83,914 | -$4,041 | -$45,221 |
| % Margin | -454.1% | -10,463.1% | -9% | -16,873.5% |
| Other Income/Exp. Net | $6,743 | $7,392 | $4,891 | -$5,919 |
| Pre-Tax Income | -$61,227 | -$76,522 | $850 | -$51,140 |
| Tax Expense | -$44 | -$3,075 | -$4,471 | -$28 |
| Net Income | -$61,074 | -$73,347 | $5,342 | -$50,865 |
| % Margin | -408% | -9,145.5% | 11.9% | -18,979.5% |
| EPS | -1.55 | -1.91 | 0.14 | -1.37 |
| % Growth | 18.8% | -1,464.3% | 110.2% | – |
| EPS Diluted | -1.55 | -1.91 | 0.14 | -1.37 |
| Weighted Avg Shares Out | 39,348 | 38,386 | 37,248 | 37,189 |
| Weighted Avg Shares Out Dil | 39,348 | 38,386 | 38,169 | 37,189 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,678 | $2,877 | $3,103 | $2 |
| Interest Expense | $53 | $28 | $19 | $2,668 |
| Depreciation & Amortization | $5,800 | $5,429 | $4,323 | $602 |
| EBITDA | -$55,374 | -$71,065 | $5,192 | -$47,870 |
| % Margin | -369.9% | -8,861% | 11.6% | -17,861.9% |